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Abstract
Background: Since the introduction of assisted reproductive technologies in 1978, over 2 million in vitro fertilization (IVF)
babies have been born worldwide. Patients play a vital role in the success of this treatment. They are required to take fertility
medication (hormone injections) to activate the ovaries to produce a sufficient number of oocytes. Later, they need to take
medication to increase the chance of the embryo surviving inside the uterus. Patients are educated during an intake consultation
at the start of the treatment to minimize the emotional burden and reduce noncompliance. The consultation lasts about 30 to 45
minutes and covers all essential subjects. Even though ample time and energy is spent on patient education, patients still feel
anxious, unknowledgeable, and unsupported. As such, electronic health utilizing a smartphone or tablet app can offer additional
support, as it allows health care professionals to provide their patients with the correct information at the right time by using push
notifications.
Objective: This randomized controlled trial aimed to evaluate the capacity of an app to support IVF patients throughout the
different phases of their treatment and assess its effectiveness. The study's primary outcome was to determine the patients’ level
of satisfaction with the information provided. The secondary outcomes included their level of knowledge, ability to administer
the medication, overall experienced quality of the treatment, health care consumption, and app usage.
Methods: This study was performed at a specialized fertility clinic of the nonacademic teaching hospital Elisabeth-TweeSteden
Ziekenhuis in Tilburg, the Netherlands. Patients who were scheduled for IVF or intracytoplasmic sperm injection treatments
between April 2018 and August 2019 were invited to participate in a physician-blinded, randomized controlled trial.
Results: In total, 54 patients participated (intervention group: n=29). Patients in the intervention group demonstrated a higher
level of satisfaction on a 0 to 10 scale (mean 8.43, SD 1.03 vs mean 7.70, SD 0.66; P=.004). In addition, they were more
knowledgeable about the different elements of the treatment on a 7 to 35 scale (mean 27.29, SD 2.94 vs mean 23.05, SD 2.76;
P<.001). However, the difference disappeared over time. There were no differences between the two patient groups on the other
outcomes. In total, 25 patients in the intervention group used the app 1425 times, an average of 57 times per patient.
Conclusions: Our study demonstrates that, in comparison with standard patient education, using an app to provide patients with
timely information increases their level of satisfaction. Furthermore, using the app leads to a higher level of knowledge about the
steps and procedures of IVF treatment. Finally, the app’s usage statistics demonstrate patients’ informational needs and their
willingness to use an electronic health application as part of their treatment.
Trial Registration: Netherlands Trial Register (NTR) 6959; https://www.trialregister.nl/trial/6959
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Introduction
Background
Since the introduction of assisted reproductive technologies in
1978, over 2 million IVF (in vitro fertilization) babies have
been born worldwide [1]. The technique offers infertile couples
the chance to become pregnant and is currently applied over a
million times annually in the United States and Europe [2-4].
An IVF or ICSI (intracytoplasmic sperm injection) treatment
has many different stages and can easily take up to several
months. First, there is the collection of oocytes (mature egg
cells) from the ovaries that need to be fertilized by sperm in a
lab. After successful fertilization, the oocytes are transferred to
the uterus (embryo transfer). Pregnancy then depends, among
different factors, on the embryos attaching to the lining of the
uterus.
Patients’ behavior and adherence to treatment instructions play
a vital role in the success of this treatment. First, they are
required to take fertility medications (hormone injections) to
activate the ovaries to produce a sufficient number of oocytes.
Later, they need to take medication to increase the chances of
the embryo surviving inside the uterus. The medication comes
with very strict regimes in terms of application and timing, and
most women suffer from the side effects of using the
medications and experience stress related to the treatment
process. Patients and clinicians report being anxious, which
often results in nonadherence to the treatment process [5,6].
Patients are educated about the process during an intake
consultation at the start of the treatment to minimize the
emotional burden and reduce the risk of noncompliance. The
consultation lasts about 30 to 45 minutes. It covers all the
important subjects, including the physiology of the menstrual
cycle, administration of the medication (and its side effects),
oocyte retrieval and embryo transfers, risks, and the chances of
becoming pregnant. Even though ample time and energy is spent
on patient education, patients still feel anxious,
unknowledgeable, and unsupported [5,7-13]. These emotions
often relate to the feeling of being uninformed. In contrast,
patients prefer being routinely provided with understandable,
structured, and practical information regarding their IVF or ICSI
treatments. [9,14-18]. Using eHealth via a smartphone or tablet
app allows health care professionals to provide their patients
with the right information at the right time through push
notifications. These notifications may refer to newly available
information, prepare patients for a consultation, or remind
patients to take their medication and provide relevant
instructions.
Furthermore, the information is readily available, complete,
well-structured, and presented in different modes like text and
video. It can utilize feedback systems to test and retest patients’
understanding of important information. A 2020 systematic
review demonstrated the effectiveness of these interventions on
many different outcomes, ranging from knowledge and
satisfaction to adherence and quality of life [19].
Objectives
This randomized controlled trial aimed to evaluate the capacity
of an app to support IVF and ICSI patients throughout the
different phases of their treatment and assess its effectiveness.
The study's primary outcome was to determine the patients’
level of satisfaction with the information provided. The
secondary outcomes included their level of knowledge, ability
to administer the medication, the overall experienced quality
of the treatment, and health care consumption. In addition, app
usage statistics were gathered to assess the need for specific
information in the app. We hypothesized that providing patients
with timely information via an app would positively affect all
outcomes compared to standard patient education practices.
Methods
Study Design
This study was performed at a specialized fertility clinic of the
nonacademic teaching hospital Elisabeth-TweeSteden
Ziekenhuis (ETZ) in Tilburg, the Netherlands. Patients who
were scheduled for IVF or ICSI treatment were invited to
participate in a physician-blinded, randomized controlled trial
between April 2018 and August 2019. The study assessed the
effectiveness of an interactive app in addition to the standard
care (website and brochures) in a parallel-group design with an
equal allocation ratio. The app was used to support and educate
patients through the different stages of their treatment, ranging
from the intake and medication instructions to the oocyte
retrieval, embryo transfer, and pregnancy test. No changes were
made to the study design after the study was initiated. We
followed the CONSORT (Consolidated Standards of Reporting
Trials) guidelines and the CONSORT eHealth checklist [20,21].
Informed Consent and Ethical Considerations
The hospital staff asked patients to consider participating in the
study following their first consultation with a fertility physician
indicating they were eligible for IVF or ICSI treatment.
Interested patients received all the necessary information about
the study, and they were offered at least 2 days to reflect on the
information. If they had any questions, they could contact the
local research coordinator (MK, gynecology resident since 2018)
by phone or email. If they agreed to participate in the study,
patients signed the informed consent before initiating their
treatment. The study was registered at the Netherlands Trial
Registry (reference number 6959). The study was approved by
the Institutional Review Board of the Maxima Medical Centre
(Eindhoven, the Netherlands; reference number N18.030) and
the ETZ hospital’s local review board.
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Patients scheduled for IVF or ICSI treatments at the ETZ
hospital were eligible for inclusion. Additionally, participants
were required to be fluent in Dutch and possess an email address
and a smartphone or tablet. For the remainder of this article, we
will refer to this patient population (patients scheduled for IVF
or ICSI treatment) as “IVF patients.”
Intervention
The Patient Journey App (Interactive Studios) provided timely
information to IVF patients in the intervention group. The app
was only available to patients in the intervention group, and
they obtained access to the app after completing the baseline
questionnaire. They received an email with download
instructions for the app and a personal code to enter on the app’s
timeline to unlock the information in the app.
All patients in the intervention group received the same
information via the app. However, the timing of the information
and push notifications was based on the date a specific patient
started the treatment and the date the patient underwent the
oocyte retrieval. These dates were entered into the system by
the hospital staff to ensure accuracy. All information, questions,
and interactions were provided within the app based on a relative
number of days before and after these events. Push notifications
were used to alert patients about the newly available information
actively. The timing of the push notifications was configured
per information item (eg, information about hormone medication
side effects was provided 3 days after the intake consultations
at 11 am, and information about the preparation for the oocyte
puncture appeared 2 days before the oocyte puncture at 8 pm).
An overview of the content, notifications, and timing is
presented in Multimedia Appendix 1.
The text, photos, and video used in the app were developed
specifically for this trial in close collaboration with a
gynecologist (JS, subspecialist reproductive medicine since
2011), a clinical embryologist (since 2004), and a specialized
fertility care nurse (since 2010). Furthermore, the electronic
health records of 10 patients who had previously undergone
IVF or ICSI treatment were checked to determine why they had
contacted the hospital. Based on this information, an interactive
timeline was developed (Figure 1). All information on the
timeline was presented in Dutch. No changes were made to the
app’s content during the trial.
Figure 1. Examples of the interactive app used as an intervention in the study (in Dutch). From left to right: introduction of the different health care
providers in the app, video and text information about medication usage and side effects, quiz-like questions to assess patient’s knowledge on various
topics, and the configuration of patient-specific medication reminders.
Information in the app was tailored to the ETZ hospital and
based on existing protocols. Patients that used the app from IVF
intake to pregnancy test after a successful embryo transfer
received 52 information items and 30 push notifications. The
information was disseminated over different phases of the IVF
or ICSI process: introduction, welcome to the ETZ fertility
center, what is IVF or ICSI, medication usage, IVF or ICSI
intake consultation, medication reminders, treatment schedule
(hormone injections, side effects, and echography), oocyte
retrieval, embryo transfer, and a pregnancy test.
Prior to the study, 4 patients were interviewed to assess the
general usefulness and usability of the app. They reported that
the app would be very useful and offered no additional
suggestions or changes. After the study, all the content
developed for the intervention was provided to the fertility
clinic, allowing them to offer it to their patients as part of the
new standard of care.
Study Outcomes
Patients’ satisfaction with the information they received during
the treatment was assessed as a primary outcome. Secondary
outcomes assessed patients’ level of knowledge, satisfaction
with the IVF intake consultation, health care consumption, and
their ability to understand the information, administer hormone
injections, and manage side effects. In addition, we assessed
patients’ overall satisfaction with the entire treatment process.
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Finally, data on app usage was continuously captured to
understand better how the app is being used over time, the type
of information that patients consult, and the videos they watch
(Textbox 1).
Textbox 1. Overview of questionnaires used per outcome.
Outcome and questionnaire
• Satisfaction with the information: A single question concerning patients’ satisfaction with the information they received during their treatment.
Numeric scale rating (NRS) scores were used to measure the outcome, ranging from 0 (not satisfied at all) to 10 (extremely satisfied).
• Level of knowledge: The patient’s perceived level of knowledge about their cycle, administration of hormone injections, side effects of hormone
injections, other medications, oocyte retrieval, embryo transfer, and pregnancy test was determined through 7 questions. All questions were
scored on a 1 to 5 scale: very knowledgeable, knowledgeable, neutral, little knowledge, and very little knowledge. Sum scores ranging from 7
to 35 were used to measure the outcome.
• General satisfaction of in vitro fertilization (IVF) intake consultation: One question assessed patients’ overall satisfaction with the IVF intake
consultation. NRS scores were used to measure the outcome, ranging from 0 (not satisfied at all) to 10 (extremely satisfied).
• Ability to understand the information during the IVF intake consultation: One question addressed patients’ ability to understand the
information presented during the IVF intake consultation. NRS scores were used to measure the outcome, ranging from 0 (no understanding at
all) to 10 (full understanding).
• Administering hormone injections: One question evaluated patients’ ability to administer the hormone injections at the right time. NRS score
was used to measure the outcome, ranging from 0 (not capable at all) to 10 (perfectly capable).
• Managing side-effects: One question assessed patients’ ability to manage treatment side effects caused by the hormone injections. NRS score
was used to measure the outcome, ranging from 0 (not capable at all) to 10 (perfectly capable).
• Overall quality of the IVF treatment: The QPP-IVF (Quality from the Patient’s Perspective of In Vitro Fertilization) questionnaire [22] assessed
3 dimensions of IVF care: medical-technical conditions (pain, physical care, and waiting time), physical-technical conditions (care room
characteristics), and identity-orientated approaches (information during and after treatment, participation, responsibility or continuity, the staffs’
respect, and empathy).
• Health care consumption: Five questions addressed contacting the hospital in the past 7 days (in addition to planned calls or visits), medication
usage, side effects, oocyte retrieval, or other topics. A 0 to 4 score was used to indicate the number of contacts.
• App usage data: Continuous logging of all the actions that patients perform in the app, such as opening the app, reading the information, and
watching a video.
The study outcomes were measured a total of 4 times during
the IVF or ICSI process (Textbox 2). The baseline measurement
was taken after patients were enrolled in the study. Follow-up
questionnaires were sent to both groups 2 days and 10 days after
the IVF intake consultation and 5 days after the oocyte retrieval.
Patients were invited to participate in the questionnaire by email.
A maximum of 2 email reminders was sent if patients did not
respond to the initial invite. Patients had a 7-day window to
complete the questionnaires for each measurement. All outcome
data were self-reported and collected using an online system.
Patients who either missed the baseline measurement or more
than 2 follow-up questionnaires were registered as lost to
follow-up. These patients were not included in the final data
analysis.
Textbox 2. Overview of outcomes assessed throughout the in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment process.
Outcomes assessed during each stage of the IVF or ICSI
• Baseline: Satisfaction with the information provided, level of knowledge, and app usage data.
• 2 days after IVF intake: Satisfaction with the information provided, level of knowledge, general satisfaction with the IVF intake consultation,
ability to understand the information during the IVF intake consultation, administering hormone injections, managing side effects, and app usage
data.
• 10 days after IVF intake: Administering hormone injections, managing side effects, app usage data, and health care consumption
• 5 days after oocyte retrieval: Satisfaction with the information provided, level of knowledge, overall quality of IVF treatment, and app usage
data
Sample Size
The sample size calculation was based on the 2016 study, which
assessed IVF patients’experiences and satisfaction with patient
information [23]. This study revealed an average satisfaction
score of 7.29 (SD 2.2) on a 0 to 10 scale. In our study, we
expected an average satisfaction of 8.5 (SD 1.5). We performed
a power calculation on powerandsamplesize.com using 2-sided
equality, α=.05, and β=.90, resulting in 33 patients in each arm.
We also added a 10% dropout margin for a total of 36 patients
in each arm.
Randomization
Patients were randomized to either the control or intervention
group by a computer program. Randomization was performed
without block or stratification restrictions. After being allocated
to one of the groups, patients received an email that included
the link to the baseline questionnaire.
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For our analysis, we used an intention-to-treat approach,
including all randomized patients. Normally distributed
continuous variables (eg, satisfaction and level of knowledge)
were presented as a mean value with the SD, and they were
statistically compared between the groups using independent
2-tailed student t-tests. Nonnormally distributed variables were
presented as a median value with the IQR. Categorical variables
(eg, health care consumption) were presented as sample number
and percentage and compared between groups using chi-square
tests. Missing data were not replaced in any type of analysis.
Patients’ level of education was divided into 2 groups for
analysis: group 1 (none, elementary school, or secondary or
vocational education) and group 2 (higher secondary education,
pre-university education, or university education in applied
sciences). P values of ≤.05 indicated a significant difference,
and P values between .05 and .10 were indicated a trend. All




Between June 2018 and August 2019, a total of 65 patients were
willing to participate in the study of which, 2 patients got
pregnant before the start of their treatment, 1 patient withdrew
due to mental instability, and 8 patients dropped out due to
logistical reasons. As a result, a total of 54 patients were
randomized into the control and intervention groups.
Of the 54 patients in the study, 4 (7.4%) did not complete the
baseline questionnaire, and 2 (3.7%) withdrew from the study
for reasons unknown. In total, 28 patients were actively enrolled
in the intervention group and 20 patients in the control group.
In the intervention group, 25 (89.3%) participants downloaded
and used the app (Figure 2). Baseline characteristics of the study
population were largely similar between groups (Table 1).
Figure 2. Patient flow diagram. OHSS: ovarian hyperstimulation syndrome.
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Table 1. Patient characteristics.
Control group (n=20)Intervention group (n=28)Characteristics
32.76 (4.55)32.39 (5.14)Age (years), mean (SD)
Education, n (%)
10 (50.0)13 (46.4)Group 1 (low)
10 (50.0)15 (53.6)Group 2 (high)
2 (1.0-3.0)2 (1.0-3.0)Years trying to get pregnant, median (IQR)
3 (15.0)2 (7.14)Prior IUIa treatment at ETZb hospital (yes), n (%)
2 (10.0)4 (14.29)Treated before in another hospital (yes), n (%)
aIUI: intrauterine insemination.
bETZ: Elisabeth-TweeSteden Ziekenhuis hospital.
Primary Outcome
Patient Satisfaction With the Information Received
During the Treatment
There was no difference between the 2 groups at baseline
(intervention group: mean 6.56, SD 1.18 vs control group: mean
6.86, SD 1.18; P=.76). However, there was a significant
difference in favor of the intervention group 2 days after the
IVF intake consultation (intervention group: mean 8.43, SD
1.03 vs control group: mean 7.70, SD 0.66; P=.004). At the
third and final measurement, 5 days after the oocyte retrieval,
the level of satisfaction was equal between groups (intervention
group: mean 8.14, SD 1.04 vs control group: mean 8.06, SD
1.44; P=.86; Table 2).
Table 2. Patient satisfaction with the information received during the treatment.
5 days after oocyte retrieval2 days after IVFa intakeBaselineSatisfaction with information
8.14 (1.04) n=228.43 (1.03) n=286.56 (1.18) n=28Intervention group, mean (SD), participants
8.06 (1.44) n=167.70 (0.66) n=206.86 (1.18) n=20Control group, mean (SD), participants
.86.004.76P value
aIVF: in vitro fertilization.
Secondary Outcomes
Level of Knowledge
There was no difference in the level of knowledge between the
2 groups at baseline (intervention group: mean 19.00, SD 3.08
vs control group: mean 17.31, SD 3.20; P=.09). However, there
was a significant difference in favor of the intervention group
2 days after the IVF intake consultation (intervention group:
mean 27.29, SD 2.94 vs control group: mean 23.05, SD 2.76;
P<.001). At the third and final measurement, 5 days after the
oocyte retrieval, the level of knowledge was slightly higher in
the intervention group, but this difference was no longer
significant (intervention group: mean 27.60, SD 3.48 vs control
group: mean 27.13, SD 4.01; P=.71; Table 3).
Table 3. Level of knowledge.
5 days after oocyte retrieval2 days after IVFa intakeBaselineLevel of knowledge
27.60 (3.48) n=2227.29 (2.94) n=2819.00 (3.08) n=28Intervention group, mean (SD), participants
27.13 (4.01) n=1623.05 (2.76) n=2017.31 (3.20) n=20Control group, mean (SD), participants
.71<.001.09P value
aIVF: in vitro fertilization.
Satisfaction With the IVF Intake Consultation and
Ability to Understand the Information
Although patients in the intervention group rated the IVF intake
consultation higher than patients in the control group, there was
no significant difference in their satisfaction levels (intervention
group: mean 9.00, SD 8.61 vs control group: mean 8.60, SD
0.94; P=.13). However, patients in the intervention group
reported a significantly higher score regarding their ability to
understand all the information provided during the consultation
(intervention group: mean 8.96, SD 1.14 vs control group: mean
7.95, SD 1.36; P=.01).
Administering Hormone Injections and Managing Side
Effects
Patients’ ability to administer the hormone injections was
measured 2 days after the IVF intake and showed no differences
between groups (intervention group: mean 8.57, SD 1.10 vs
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control group: mean 8.15, SD 1.73; P=.31). This outcome was
measured again 10 days after the IVF intake consultation with
similar results (intervention group: mean 8.74, SD 1.20 vs
control group: mean 8.26, SD: 1.94; P=.23).
Patients’ ability to manage the side effects of the hormone
injections was measured 2 days after the IVF intake consultation
and showed no differences between groups (intervention group:
mean 7.43, SD 1.60 vs control group: mean 7.15, SD 1.47;
P=.54). It was measured again 10 days after the IVF intake
consultation with similar results (intervention group: mean 7.52,
SD 1.06 vs control group: mean 7.42, SD 1.43; P=.79).
Overall Quality of the IVF Treatment
There was no difference between the groups regarding the
perceived overall quality of the IVF treatment (intervention
group: mean 51.65, SD 12.73 vs control group: mean 48.59,
SD 9.55; P=.41).
Health Care Consumption
A trend was observed between the 2 groups concerning health
care consumption. Patients in the intervention group contacted
the hospital less frequently (intervention group: mean 0.44
contacts per patient, SD 0.85 vs control group: mean 0.84
contacts per patient, SD 0.69; P=.09).
App Usage Data
In total, 25 patients in the intervention group used the app 1425
times, an average of 57 times per patient. Patients primarily
used a smartphone to access the information (1283/1425, 90%)
compared to tablet use (142/1425, 10%). Hormone injection
instructions, the side effects of medication, the first day of the
IVF cycle, the oocyte retrieval, and usage of the medication
capsules after the embryo transfer were consulted most
frequently. During the intervention, 26 videos were offered to
each patient on average. In total, these videos were viewed 618
times, an average of 24 views per patient. In addition,
video-enriched information items about the start of the IVF
cycle, medication side effects, oocyte retrieval, and embryo
transfer were frequently viewed.
Post-Hoc Power Analysis
Unfortunately, we could not include as many patients as we
required based on the initial power calculation we performed.
Therefore, to determine the strength of our results, we performed
a post-hoc power calculation based on the results of our primary
outcome (ie, satisfaction with the information two days after
the IVF intake). It showed a power of 81%, indicating that our
study was not underpowered.
Discussion
Principal Findings
The results of our study demonstrate the effectiveness of using
an app to educate and support patients that undergo IVF
treatment. Regarding the primary outcome, patients in the
intervention group were more satisfied with the information
they received, especially in the first stages of their treatment.
Furthermore, the app positively affected patients’ knowledge
about the different aspects of their IVF treatment and their
ability to understand the information during the intake
consultation.
To our knowledge, our study is the first to assess the
effectiveness of using an app to educate IVF patients through
the different stages of their treatment, offering the information
promptly by using push notifications. The results on outcomes
such as satisfaction and level of knowledge are in line with a
2020 review on using apps to educate patients in this timely
manner [19]. Satisfactory patient information and the feeling
of a (virtual) continuity of care have been indirectly associated
with better individual well-being by reducing treatment concerns
and enabling higher treatment tolerability [24]. The importance
of information provisioning was also demonstrated by a large
European study focusing on patient-centered care in fertility
clinics [25]. Being more responsive to patients’ needs and
expectations can lower the number of discontinued treatments
because it reduces the level of emotional distress [26]. However,
the results on medication adherence and the management of
side effects differ from previous studies, where patients reported
anxiety concerning these topics [11,27]. In our study,
participants in both groups reported similar positive scores on
their ability to manage their medication regimens.
Strengths and Limitations
An important strength of our study is content development, for
which we combined multiple insights from specialized fertility
physicians and nurses, and embryologists. Another strength is
push notifications, allowing the app to reach out to patients
when new information was available actively. By delivering
the most relevant information in smaller segments, patients can
better process and retain the information [19,28]. The app usage
statistics demonstrate patients’willingness and need for the app,
and that offering complex topics such as the start of the cycle,
the oocyte retrieval, side effects of medication, and the embryo
transfer through video is highly appreciated.
Limitations
An essential limitation of the study is that we could not include
as many patients as required based on the initial power
calculation. It was mainly due to staffing problems at the
hospital. Nevertheless, a post-hoc power analysis was performed
to determine the strength of our results, demonstrating that our
study was not underpowered. In addition, we did not involve
patient input when deciding which content to offer through the
app, including the format and timing of push notifications. This
could have contributed to a more personalized experience.
Finally, we used several self-reported questionnaires. Although
not scientifically validated, we presented the questionnaires to
patients prior to the study initiation and used the commonly
applied 0 to 10 numeric rating scale mechanism to score the
items.
Clinical Implications and Future Research
All patients in the intervention group could download and use
the app with no additional instructions besides those provided
in the initial email, positively demonstrating the ease and
acceptance of the intervention from a patient perspective. It also
means that implementing such an app does not require the
hospital staff to alter their routines to support patients with the
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app. In its current form, the app optimizes the IVF patient
journey without requiring additional staff resources.
Future development and research should focus on a more
personalized version of the app, including a more qualitative
approach to better identify patients’ needs and new strategies
to ensure the information suits their communication styles
[29-31]. In addition, adjusting the information based on a
patient's anxiety or depression during the different stages of the
treatment can enable patients to better cope with the emotional
burden of undergoing the treatment and managing related
outcomes [32-34].
The app use might be extended to other phases of the IVF
treatments or other treatments as well, not only to inform
patients about the next step in their treatment but also to actively
involve them in their treatment. For example, it would be
interesting to see if the patient and health care provider’s
reported quality of the first consultation would change when
patients primarily use the app for educational purposes and
in-person clinic visits are spent addressing questions and their
priorities. In addition, using the app as a communication
platform between patients and health care providers during the
entire care journey could further optimize the perceived quality
of care. Previous studies focusing on online IVF platforms
reported positive outcomes on such ideas, but only if they are
strategically implemented in the clinic as integral to the standard
of care [35,36].
Conclusions
Our study demonstrates that, in comparison with standard patient
education, using an app to provide patients with timely
information increases their level of satisfaction. Furthermore,
using the app leads to a higher level of knowledge regarding
the steps and procedures of IVF treatment. The app’s usage
statistics demonstrate patients’ need for information and their
willingness to use an eHealth application as part of their
treatment. Future interventions might use a better
patient-centered approach, for instance, collecting information
about patients’ needs and expectations in preparation for their
initial consultations or the treatment itself.
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